Stratagene ( entered into a joint development and license agreement with Rosetta Inpharmatics ( to create an automated solution for the isolation of nucleic acids from a variety of clinical samples. Stratagene and Rosetta will develop an instrument and a single-use consumable that will be manufactured and commercialized by Stratagene. These products will be sold to Stratagene’s current customer base and companies engaged in pharmacogenomics.

Previous articleHIV Drug Distribution Agreement
Next articleNovel Protein-Genome Interaction Mapping Technology Developed by Leading Research Institutes